Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

The future of malaria control in Africa has to be anchored in quality data, quality assured data that countries can have complete ownership of, and they begin to use to design the future of malaria control.

I think there is too much emphasis at the moment on models that are generated in the north. There is far too little use of data that exists in African countries, to support African governments in their decision-making. There needs to be a complete seed change in this use of evidence, and this is what this project is all about. Basically, it's about increasing the capacity of countries to assemble the information that exists within their national borders and how they might use that to change the future.

The link programme as it is now is based at the London School of Hygiene and Tropical Medicine but it had an earlier history as it were, which began in Nairobi about two or three years ago. We started working with the Kenyan government to try and assemble all the malaria epidemiological evidence, so that they could better design the distribution of insecticide treated bed nets, distribution of ACTs (Artemisinin based Combination Therapies), IRS (Indoor Residual Spraying) and what they might do to improve progress towards reducing malaria morbidity and mortality in Kenya. That was really a science and government collaboration where we were assembling the data, spatially modelling the data, working closely with the National Malaria Control Programme. That relationship worked really well; it helped the Kenyan government secure money from the Global Fund, helped them design their National Malaria Strategy, and was actually a classic example of assembling epidemiological data to design control. I would say it was probably one of the first times it has been done for over 20 or 30 years in Africa. At the time that the Roll Back Malaria initiative started, things were so bad across Africa, everybody just did everything, irrespective of what the epidemiology was. You just threw everything and the kitchen sink at malaria, ATCs everywhere, bed nets everywhere, irrespective of whether or not people needed it, or it had been most effective.

After 10 years, we began to nuance that and fine-tune it using data. We have been working from the Kenyan Medical Research Institute in Nairobi; we have been working with other countries in Somalia, Djibouti and Sudan to do similar things. The Department for International Development from the UK thought that this was something that was needed beyond our sub-region, across Africa, and they asked us to form a project that would do an epidemiological assessment in 8 countries.

That was a difficult job because there was lots of data available but the National Malaria Control Programmes hadn't pulled it all together in one centralised set of data bases. That was part of our job, to actually find all this data that was held by different research groups, different NGO groups, and pull it all together, put it on maps, model it and begin to develop an intelligence as it were, what we call a Malaria Intelligence System.

In the initial phase, we worked in the Democratic Republic of Congo, Tanzania, Uganda, Ethiopia, Malawi, Mali, Ghana and Nigeria. It took us a year to complete all those epidemiological profiles. We engaged with the National Malaria Control Programmes in each of those countries, and with the research partners that helped and support them provide the evidence in-country. I would say that one of the strengths of that, which wasn't an anticipated strength, was bringing research and policy control communities together. In some instances, it was the first time that they had opened up a real dialogue as to how you might use epidemiological science to design control.

Now the ambition is to try and do that in 22 countries, try and support those countries in building up an evidence base, and get them to think - and I mean this in the nicest possible way - intelligently about designing control, so that they are rational with the use of their resources and likely to have the biggest benefit.

Bob Snow

Malaria & Public Health

Professor Bob Snow has developed a large programme of work on the phenotype of malaria disease, its relationship to parasite exposure and its wider public health burden.
Technical advisor to the Kenyan Government (and member of a number of international malaria advisory panels), Professor Snow provides the bridge between basic malaria epidemiology and malaria control policy in the region.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Lorenz von Seidlein: Malaria elimination in the Greater Mekong sub-region

Multidrug resistant P. falciparum malaria is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for artemisinin combination therapies, the main falciparum malaria medicines.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.